OncLive SOSS

Authors

Nikita Sinha, MD

Latest:

Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Craig Eckfeldt, MD, PhD

Latest:

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Carrie Horton, MS, CGC

Latest:

Horton on Addressing the Equity Gap of Genetic Testing in Cancer Care

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Pavani Chalasani, MD, MPH

Latest:

Dr Chalasani on the Potential Utility of Eftilagimod Alpha in HER2–/HER2-Low Breast Cancer

Pavani Chalasani, MD, MPH, discusses the potential clinical significance of the AIPAC-003 trial of eftilagimod alpha in HER2–/HER2-low breast cancer.

Latest:

Dr Qin on Areas of Active and Future Investigation in NSCLC

Angel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.

Latest:

Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Sailaja Kamaraju, MD

Barry W. Goy, MD

Barry W. Goy, MD, is a physician in the Department of Radiation Oncology at Kaiser Permanente.

Latest:

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Kathleen O’Brien

Latest:

The Desire to Always Do More

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Marlana M. Orloff, MD, Thomas Jefferson University Hospital

Latest:

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Annie Im, MD, FASCO

Latest:

Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024

Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.

Haeseong Park, MD, MPH

Latest:

Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal Cancer

Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Gordana Vunjak-Novakovic, PhD, BS, MS

Latest:

Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Antonio Martin Jimenez Jimenez, MD

Latest:

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Debra L. Richardson, MD, FACS, FACOG

Latest:

Long-Term Safety and Efficacy of Selinexor Maintenance Treatment in Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer: Follow-up Subgroup Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study

Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial, showing that selinexor maintenance therapy significantly improves progression-free survival and delays subsequent treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer, with manageable safety and potential long-term benefit.

Monica M. Mita, MD

Latest:

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Sanjay Popat, BSc, MBBS, FRCP, PhD

Latest:

Dr Popat on the Efficacy and Safety Profiles of Zongertinib in HER2-Mutated NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

Latest:

Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.

Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.

Suchita Pakkala, MD

Latest:

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Katherine Clifton, MD

Latest:

Insights From SABCS 2024 and Future Directions in Breast Cancer

Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.

x